fluticasone furoate/umeclidinium/vilanterol vs Tiotropium bromide

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline

fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta

Marketed by GlaxoSmithKline

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Reliable signal

NCT02164513 · Phase 3 · completed

This was a large randomized, double-blind, active-controlled trial in 10,355 COPD patients at 971 sites in 37 countries; the primary endpoint, annual on-treatment moderate/severe exacerbation rate, is a hard clinical outcome, and triple therapy significantly reduced exacerbations versus both dual-therapy comparators (rate ratio 0.75 vs UMEC/VI and 0.85 vs FF/VI, both p<0.001).

Next expected readout: September 2027 · NCT07192016 (registry estimate)

Reported efficacy

Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI (Up to Week 52): Annual rate of on-treatment moderate/severe exacerbations: FF/UMEC/VI 0.91/yr vs FF/VI 1.07/yr (rate ratio 0.85, 95% CI 0.80-0.90, 15% reduction, p<0.001) vs UMEC/VI 1.21/yr (rate ratio 0.75, 95% CI 0.70-0.81, 25% reduction, p<0.001) (met)

Result source: NCT02164513

Tiotropium bromide

Marketed by Boehringer Ingelheim

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule
Partial signal

NCT02172287 · Phase 3 · completed

This 6-month trial randomly assigned 623 patients with COPD to tiotropium, salmeterol or placebo, with double-blind, double-dummy treatment. The two primary measures were trough FEV1 and the Transition Dyspnea Index (TDI). Tiotropium raised trough FEV1 by 0.14 L more than placebo, more than salmeterol did (0.09 L; p<0.01 for tiotropium against salmeterol), and improved the TDI focal score by 1.02 units against placebo (p=0.01). Both primary measures favoured tiotropium, so the result is met. The figures come from the peer-reviewed paper in Chest (2002).

Reported efficacy

Change from baseline in trough Forced expiratory volume in one second (FEV1) response (baseline, up to day 169); Change from baseline in Mahler Transitional Dyspnoea Index (TDI) (baseline, up to day 169): Primary 1, trough (predose morning) FEV1 change at 6 months vs placebo: tiotropium +0.14 L, salmeterol +0.09 L (tiotropium vs salmeterol p<0.01), met. Primary 2, TDI focal score at 6 months: tiotropium +1.02 units vs placebo (p=0.01), met; salmeterol +0.24 units, not significant. (met)

Result source: NCT02172287

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfluticasone furoate/​umeclidinium/​vilanterolTiotropium bromide
Moderate or severe exacerbations, annualised rate0.9 vs 1.1vs FF/VIwk 52 · n 4145NCT02164513
2 other results
  • 0.2 vs 0.3 100/62.5/25 µg · wk 24 · n 907 · Phase 3 · secondary NCT02345161
  • 0.2 vs 0.4 100/62.5/25 µg · wk 52 · n 210 · Phase 3 · secondary NCT02345161
0.9 vs 1.3−0.4 vs placebo18μg · n 54NCT01663987
1 other result
  • 0.9 vs 1.3 18 μg · n 54 · Phase 4 · secondary NCT01662986
Trough FEV1, change0.1 vs -0.0vs BUD/FOR100/62.5/25 µg · wk 24 · n 836NCT02345161
14 other results
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.1 vs -0.1 100/62.5/25 µg · wk 52 · n 183 · Phase 3 · primary NCT02345161
  • 0.1 vs -0.0 wk 52 · n 3366 · Phase 3 · secondary NCT02164513
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 362 · Phase 4 · primary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 376 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs -0.0 100/62.5/25 mcg · wk 4 · n 385 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 358 · Phase 4 · secondary NCT03478683
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 0.29 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs 0.0 100/62.5/25 mcg · wk 0.29 · n 358 · Phase 4 · secondary NCT03478683
0.1 vs 0.1vs AB400/12 μg · wk 24 · n 314NCT02796677
42 other results
  • 0.2 vs -0.1 18μg · wk 12 · n 30 · Phase 4 · primary NCT01663987
  • 0.2 vs 0.1 18 μg · wk 12 · n 30 · Phase 4 · primary NCT01662986
  • 0.1 vs 0.1 10 μg · wk 3 · n 30 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 40 μg · wk 3 · n 31 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 20 μg · wk 3 · n 32 · Phase 2 · primary NCT03118765
  • 0.2 vs 0.1 5/10 μg · wk 4 · n 88 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/2 μg · wk 4 · n 89 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/5 μg · wk 4 · n 93 · Phase 2 · primary NCT00696020
  • 0.1 vs -0.0 wk 12 · n 152 · Phase 4 · primary NCT00359788
  • 0.1 vs -0.0 200 mcg · wk 18 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 12 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 8 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 4 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 2 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 1 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 18 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 12 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 8 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 4 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 2 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 1 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 18 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 12 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 8 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 4 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 2 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 1 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.2 vs 0.0 18μg · wk 12 · n 60 · Phase 4 · secondary NCT01663987
  • 0.2 vs 0.0 18 μg · wk 12 · n 60 · Phase 4 · secondary NCT01662986
  • 0.1 vs 0.0 200 mcg · wk 0.71 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 200 mcg · wk 0.43 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.71 · n 56 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.43 · n 56 · Phase 2 · secondary NCT00528996
  • 0.0 vs 0.0 50 mcg · wk 0.71 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 50 mcg · wk 0.43 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 wk 6 · n 152 · Phase 4 · secondary NCT00359788
SGRQ total, change-6.6 vs -4.3vs BUD/FOR100/62.5/25 µg · wk 24 · n 846NCT02345161
3 other results
  • -4.6 vs -1.9 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · primary NCT02345161
  • -5.5 vs -3.7 wk 52 · n 3318 · Phase 3 · secondary NCT02164513
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
-4.1 vs -2.0−2.1 vs placebowk 12 · n 315NCT00496470
TDI focal score2.3 vs 1.7vs BUD/FOR100/62.5/25 µg · wk 24 · n 839NCT02345161
1 other result
  • 1.7 vs 1.4 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · secondary NCT02345161
—Not posted · NCT02172287

Moderate or severe exacerbations, annualised rate

fluticasone furoate/​umeclidinium/​vilanterol
0.9 vs 1.1vs FF/VIwk 52 · n 4145NCT02164513
2 other results
  • 0.2 vs 0.3 100/62.5/25 µg · wk 24 · n 907 · Phase 3 · secondary NCT02345161
  • 0.2 vs 0.4 100/62.5/25 µg · wk 52 · n 210 · Phase 3 · secondary NCT02345161
Tiotropium bromide
0.9 vs 1.3−0.4 vs placebo18μg · n 54NCT01663987
1 other result
  • 0.9 vs 1.3 18 μg · n 54 · Phase 4 · secondary NCT01662986

Trough FEV1, change

fluticasone furoate/​umeclidinium/​vilanterol
0.1 vs -0.0vs BUD/FOR100/62.5/25 µg · wk 24 · n 836NCT02345161
14 other results
  • 0.1 vs 0.1 100/62.5/25 · wk 24 · n 307 · Phase 3 · primary NCT02729051
  • 0.1 vs -0.1 100/62.5/25 µg · wk 52 · n 183 · Phase 3 · primary NCT02345161
  • 0.1 vs -0.0 wk 52 · n 3366 · Phase 3 · secondary NCT02164513
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 362 · Phase 4 · primary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12.14 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs 0.0 100/62.5/25 mcg · wk 12 · n 376 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 12 · n 358 · Phase 4 · secondary NCT03478683
  • 0.1 vs -0.0 100/62.5/25 mcg · wk 4 · n 385 · Phase 4 · secondary NCT03474081
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 4 · n 358 · Phase 4 · secondary NCT03478683
  • 0.0 vs -0.0 100/62.5/25 mcg · wk 0.29 · n 355 · Phase 4 · secondary NCT03478696
  • 0.0 vs 0.0 100/62.5/25 mcg · wk 0.29 · n 358 · Phase 4 · secondary NCT03478683
Tiotropium bromide
0.1 vs 0.1vs AB400/12 μg · wk 24 · n 314NCT02796677
42 other results
  • 0.2 vs -0.1 18μg · wk 12 · n 30 · Phase 4 · primary NCT01663987
  • 0.2 vs 0.1 18 μg · wk 12 · n 30 · Phase 4 · primary NCT01662986
  • 0.1 vs 0.1 10 μg · wk 3 · n 30 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 40 μg · wk 3 · n 31 · Phase 2 · primary NCT03118765
  • 0.1 vs 0.1 20 μg · wk 3 · n 32 · Phase 2 · primary NCT03118765
  • 0.2 vs 0.1 5/10 μg · wk 4 · n 88 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/2 μg · wk 4 · n 89 · Phase 2 · primary NCT00696020
  • 0.1 vs 0.1 5/5 μg · wk 4 · n 93 · Phase 2 · primary NCT00696020
  • 0.1 vs -0.0 wk 12 · n 152 · Phase 4 · primary NCT00359788
  • 0.1 vs -0.0 200 mcg · wk 18 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 12 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 8 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 4 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 2 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 200 mcg · wk 1 · n 387 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 18 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 12 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 8 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 4 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 2 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 100 mcg · wk 1 · n 409 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 18 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 12 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 8 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 4 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 2 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 50 mcg · wk 1 · n 417 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 24 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.1 wk 16 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.1 vs -0.0 wk 8 · n 227 · Phase 4 · secondary NCT00523991
  • 0.2 vs 0.0 18μg · wk 12 · n 60 · Phase 4 · secondary NCT01663987
  • 0.2 vs 0.0 18 μg · wk 12 · n 60 · Phase 4 · secondary NCT01662986
  • 0.1 vs 0.0 200 mcg · wk 0.71 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 200 mcg · wk 0.43 · n 54 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.71 · n 56 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 100 mcg · wk 0.43 · n 56 · Phase 2 · secondary NCT00528996
  • 0.0 vs 0.0 50 mcg · wk 0.71 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs 0.0 50 mcg · wk 0.43 · n 58 · Phase 2 · secondary NCT00528996
  • 0.1 vs -0.0 wk 6 · n 152 · Phase 4 · secondary NCT00359788

SGRQ total, change

fluticasone furoate/​umeclidinium/​vilanterol
-6.6 vs -4.3vs BUD/FOR100/62.5/25 µg · wk 24 · n 846NCT02345161
3 other results
  • -4.6 vs -1.9 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · primary NCT02345161
  • -5.5 vs -3.7 wk 52 · n 3318 · Phase 3 · secondary NCT02164513
  • -5.8 vs -4.9 100/62.5/25 · wk 24 · n 489 · Phase 3 · secondary NCT02729051
Tiotropium bromide
-4.1 vs -2.0−2.1 vs placebowk 12 · n 315NCT00496470

TDI focal score

fluticasone furoate/​umeclidinium/​vilanterol
2.3 vs 1.7vs BUD/FOR100/62.5/25 µg · wk 24 · n 839NCT02345161
1 other result
  • 1.7 vs 1.4 100/62.5/25 µg · wk 52 · n 182 · Phase 3 · secondary NCT02345161
Tiotropium bromide
—Not posted · NCT02172287
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety

Coverage. fluticasone furoate/umeclidinium/vilanterol: 5 of 5 rows · Tiotropium bromide: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfluticasone furoate/​umeclidinium/​vilanterol
Rows use multiple source trials
Tiotropium bromide
Rows use multiple source trials
FEV1
absolute change · L
No placebo or comparator arm
0.132 L @ 12wka,b,c,d
NCT05535972 · Phase 4 · registry result, not featured evidence
1.651 L @ 4wk5 mcge,a,b,c,d
NCT02683668 · Phase 3 · registry result, not featured evidence
show 2 more doses
1.58 L @ 4wk18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
1.575 L @ 4wk18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
Dropout rate
10.5%FF/UMEC/VIf
NCT02164513 · Phase 3
show 9 more results
—100/62.5/25
NCT02164513 · Phase 3
4.9%100/62.5/25 µg
NCT02345161 · Phase 3
6.1%
NCT04923347 · Phase 4 · registry result, not featured evidence
9.5%
NCT05535972 · Phase 4 · registry result, not featured evidence
3%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
NCT03467425 · Phase 4 · registry result, not featured evidence
4.3%100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
4.6%100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
3.6%100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
5.7%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
10.3%50/250 µg BIDf
NCT01762800 · Phase 4 · registry result, not featured evidence
show 37 more results
—50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
—18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
15%18μg
NCT01663987 · Phase 4 · registry result, not featured evidence
33.3%18 μg
NCT01662986 · Phase 4 · registry result, not featured evidence
—50/250 µg BID
NCT01751113 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
11.3%
NCT00523991 · Phase 4 · registry result, not featured evidence
7.9%
NCT00496470 · Phase 4 · registry result, not featured evidence · combination
13.3%
NCT00359788 · Phase 4 · registry result, not featured evidence
—
NCT03137992 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
0%18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
23.2%5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
23%18 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
23.4%2.5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
—150 μg
NCT00999908 · Phase 3 · registry result, not featured evidence
13.3%10 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
16.1%40 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
6.3%20 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—18 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
4.5%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
2.2%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
3.2%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
3.9%FF/UMEC/VIf
NCT02164513 · Phase 3
show 9 more results
—100/62.5/25
NCT02164513 · Phase 3
1.8%100/62.5/25 µg
NCT02345161 · Phase 3
—
NCT04923347 · Phase 4 · registry result, not featured evidence
1.3%
NCT05535972 · Phase 4 · registry result, not featured evidence
0.6%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
NCT03467425 · Phase 4 · registry result, not featured evidence
1.5%100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
0.3%100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
1.4%100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
6.4%50/250 µg BIDf
NCT01762800 · Phase 4 · registry result, not featured evidence
show 37 more results
—50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
—18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
5%18μg
NCT01663987 · Phase 4 · registry result, not featured evidence
10.3%18 μg
NCT01662986 · Phase 4 · registry result, not featured evidence
—50/250 µg BID
NCT01751113 · Phase 4 · registry result, not featured evidence
—50/250 µg BID + 18 µg QD
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
2.1%
NCT00523991 · Phase 4 · registry result, not featured evidence
2.4%
NCT00496470 · Phase 4 · registry result, not featured evidence · combination
6.4%
NCT00359788 · Phase 4 · registry result, not featured evidence
—
NCT03137992 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
10.6%5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
11.1%18 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
10.5%2.5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
—150 μg
NCT00999908 · Phase 3 · registry result, not featured evidence
3.3%10 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
3.2%40 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
3.1%20 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—18 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
—tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
—tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
1.1%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
1.1%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
2.2%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
—FF/UMEC/VIf
NCT02164513 · Phase 3
show 9 more results
21.6%100/62.5/25
NCT02164513 · Phase 3
6.7%100/62.5/25 µg
NCT02345161 · Phase 3
0.4%
NCT04923347 · Phase 4 · registry result, not featured evidence
4.1%
NCT05535972 · Phase 4 · registry result, not featured evidence
7.4%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
NCT03467425 · Phase 4 · registry result, not featured evidence
3.3%100/62.5/25 mcg
NCT03474081 · Phase 4 · registry result, not featured evidence
4.4%100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
8%100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
10.4%100/62.5/25
NCT02729051 · Phase 3 · registry result, not featured evidence
—50/250 µg BIDf
NCT01762800 · Phase 4 · registry result, not featured evidence
show 37 more results
5.9%50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence
8.8%50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
10.7%18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
37.5%18μg
NCT01663987 · Phase 4 · registry result, not featured evidence
25.6%18 μg
NCT01662986 · Phase 4 · registry result, not featured evidence
0%50/250 µg BID
NCT01751113 · Phase 4 · registry result, not featured evidence
3.8%50/250 µg BID + 18 µg QD
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
4.2%
NCT00523991 · Phase 4 · registry result, not featured evidence
3%
NCT00496470 · Phase 4 · registry result, not featured evidence · combination
6.4%
NCT00359788 · Phase 4 · registry result, not featured evidence
0%
NCT03137992 · Phase 3 · registry result, not featured evidence
—5 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
—18 mcg
NCT02683668 · Phase 3 · registry result, not featured evidence
7.3%400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
32.9%5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
33.9%18 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
33.8%2.5 mcg
NCT01126437 · Phase 3 · registry result, not featured evidence
0%150 μg
NCT00999908 · Phase 3 · registry result, not featured evidence
0%10 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
0%40 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
0%20 μg
NCT03118765 · Phase 2 · registry result, not featured evidence
2%5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
1.4%18 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
0%2.5 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
1.4%1.25 mcg
NCT01222533 · Phase 2 · registry result, not featured evidence
3.7%5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
1.8%10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence
0%tiotropium 5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
4.5%tiotropium 2.5 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
2.7%tiotropium 2.5 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 1.25 mcg + olodaterol 10 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0.9%tiotropium 1.25 mcg + olodaterol 5 mcg
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
0%5/10 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
3.4%5/2 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
1.1%5/5 μg
NCT00696020 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
100/62.5/25f
viral upper respiratory tract infection 12.5%
upper respiratory tract infection 7.2%
headache 5.6%
NCT02164513 · Phase 3
show 8 more results
100/62.5/25 µg
nasopharyngitis 7.9%
headache 4.8%
NCT02345161 · Phase 3
pyrexia 4.4%
headache 3.9%
NCT04923347 · Phase 4 · registry result, not featured evidence
dysphonia 0.4%
abdominal discomfort 0.2%
abdominal pain upper 0.2%
NCT05535972 · Phase 4 · registry result, not featured evidence
100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
dyspnoea 2.1%
NCT03467425 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
headache 4.5%
nasopharyngitis 4%
NCT03474081 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
headache 3.6%
nasopharyngitis 1.9%
NCT03478696 · Phase 4 · registry result, not featured evidence
100/62.5/25 mcg
nasopharyngitis 5%
NCT03478683 · Phase 4 · registry result, not featured evidence
100/62.5/25
viral upper respiratory tract infection 10.6%
headache 6.1%
upper respiratory tract infection 3.4%
NCT02729051 · Phase 3 · registry result, not featured evidence
50/250 µg BIDf
nasopharyngitis 18.4%
dysphonia 13.2%
bronchitis 5.1%
NCT01762800 · Phase 4 · registry result, not featured evidence
show 27 more results
50/250 µg BID + 18 µg QD
nasopharyngitis 20.6%
bronchitis 10.3%
dysphonia 8.8%
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
18 µg QD + 50/250 µg BID
nasopharyngitis 26.7%
dysphonia 8%
bronchitis 6.7%
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
18μg
chronic obstructive pulmonary disease 37.5% (placebo 43.6%)
bronchitis 7.5% (placebo 5.1%)
insomnia 5% (placebo 5.1%)
NCT01663987 · Phase 4 · registry result, not featured evidence
18 μg
chronic obstructive pulmonary disease 25.6% (placebo 15.4%)
contusion 7.7% (placebo 0%)
oedema peripheral 7.7% (placebo 0%)
NCT01662986 · Phase 4 · registry result, not featured evidence
50/250 µg BID
dysphonia 5.9%
constipation 2%
dry mouth 2%
NCT01751113 · Phase 4 · registry result, not featured evidence
50/250 µg BID + 18 µg QD
dysphonia 9.6%
nasopharyngitis 5.8%
arthralgia 3.8%
NCT01751113 · Phase 4 · registry result, not featured evidence · combination
nasophayngitis 6.7% (placebo 5%)
chronic obstructive pulmonary disease 4.6% (placebo 9.6%)
NCT00523991 · Phase 4 · registry result, not featured evidence
chronic obstructive pulmonary disease 6.4%
NCT00359788 · Phase 4 · registry result, not featured evidence
400/12 μg
chronic obstructive pulmonary 15.6%
nasopharyngitis 11.5%
headache 5.1%
NCT02796677 · Phase 3 · registry result, not featured evidence
5 mcg
chronic obstructive pulmonary disease 32.9%
NCT01126437 · Phase 3 · registry result, not featured evidence
18 mcg
chronic obstructive pulmonary disease 33.9%
NCT01126437 · Phase 3 · registry result, not featured evidence
2.5 mcg
chronic obstructive pulmonary disease 33.8%
NCT01126437 · Phase 3 · registry result, not featured evidence
10 μg
cough 3.3% (placebo 0%)
headache 3.3% (placebo 3%)
urinary tract infection 3.3% (placebo 3%)
NCT03118765 · Phase 2 · registry result, not featured evidence
40 μg
dry mouth 12.9% (placebo 0%)
dizziness 3.2% (placebo 6.1%)
back pain 0% (placebo 3%)
NCT03118765 · Phase 2 · registry result, not featured evidence
20 μg
back pain 6.3% (placebo 3%)
headache 6.3% (placebo 3%)
cough 3.1% (placebo 0%)
NCT03118765 · Phase 2 · registry result, not featured evidence
5 mcg
nasopharyngitis 9.3% (placebo 4.1%)
dyspnoea 2% (placebo 9.5%)
NCT01222533 · Phase 2 · registry result, not featured evidence
18 mcg
nasopharyngitis 4.8% (placebo 4.1%)
dyspnoea 2.1% (placebo 9.5%)
NCT01222533 · Phase 2 · registry result, not featured evidence
2.5 mcg
dyspnoea 1.4% (placebo 9.5%)
nasopharyngitis 1.4% (placebo 4.1%)
NCT01222533 · Phase 2 · registry result, not featured evidence
1.25 mcg
nasopharyngitis 6.1% (placebo 4.1%)
dyspnoea 3.4% (placebo 9.5%)
NCT01222533 · Phase 2 · registry result, not featured evidence
5 mcg
nasopharyngitis 10.2%
chronic obstructive pulmonary disease 5.6%
NCT01040403 · Phase 2 · registry result, not featured evidence
10 mcg
nasopharyngitis 6.4%
chronic obstructive pulmonary disease 5.5%
NCT01040403 · Phase 2 · registry result, not featured evidence
tiotropium 5 mcg + olodaterol 10 mcg
chronic obstructive pulmonary disease 3.6%
nasopharyngitis 1.8%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 5 mcg + olodaterol 5 mcg
chronic obstructive pulmonary disease 7.3%
nasopharyngitis 2.8%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 2.5 mcg + olodaterol 10 mcg
nasopharyngitis 3.6%
chronic obstructive pulmonary disease 2.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 2.5 mcg + olodaterol 5 mcg
nasopharyngitis 7.1%
chronic obstructive pulmonary disease 2.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 1.25 mcg + olodaterol 10 mcg
nasopharyngitis 7.3%
chronic obstructive pulmonary disease 6.4%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination
tiotropium 1.25 mcg + olodaterol 5 mcg
nasopharyngitis 11%
chronic obstructive pulmonary disease 3.7%
NCT01040403 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aTrial phases differ: Phase 3 versus Phase 4.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dAssessment timepoints differ: 4 weeks versus 12 weeks.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

fluticasone furoate/umeclidinium/vilanterol

Time to First Moderate or Severe Exacerbation NA vs NA FF/VI months @ 52wk
time to event · months
Median time to onset
NCT02164513 · Phase 3
show 1 more result
NA vs 8.31 UMEC/VI months @ 52wk
Median time to onset
NCT02164513 · Phase 3
TDI Focal 2.29 vs 1.72 BUD/FOR score @ 24wk100/62.5/25 µg
absolute change · score
NCT02345161 · Phase 3
show 1 more result
1.74 vs 1.39 BUD/FOR score @ 52wk100/62.5/25 µg
NCT02345161 · Phase 3
EXACT-RS -1.45 vs -0.5 BUD/FOR score @ 4wk100/62.5/25 µg
absolute change · score
NCT02345161 · Phase 3
show 17 more results
-2 vs -0.77 BUD/FOR score @ 8wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.23 vs -1.05 BUD/FOR score @ 12wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.42 vs -1.09 BUD/FOR score @ 16wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.43 vs -1.02 BUD/FOR score @ 20wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.31 vs -0.96 BUD/FOR score @ 24wk100/62.5/25 µg
NCT02345161 · Phase 3
-1.24 vs -0.72 BUD/FOR score @ 4wk100/62.5/25 µg
NCT02345161 · Phase 3
-1.97 vs -0.9 BUD/FOR score @ 8wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.18 vs -1.21 BUD/FOR score @ 12wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.53 vs -1.52 BUD/FOR score @ 16wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.64 vs -1.53 BUD/FOR score @ 20wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.63 vs -1.52 BUD/FOR score @ 24wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.48 vs -1.16 BUD/FOR score @ 28wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.33 vs -0.9 BUD/FOR score @ 32wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.12 vs -0.62 BUD/FOR score @ 36wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.34 vs -1.11 BUD/FOR score @ 40wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.3 vs -0.81 BUD/FOR score @ 44wk100/62.5/25 µg
NCT02345161 · Phase 3
-2.17 vs -0.64 BUD/FOR score @ 48wk100/62.5/25 µg
NCT02345161 · Phase 3
EXACT-RS -2.03 vs -0.61 BUD/FOR score @ 52wk100/62.5/25 µg
absolute change · score
EXACT-RS Scores, Week 49-52, n=179, 171
NCT02345161 · Phase 3
FEV1 Trough 0.0542 L @ 4wk
absolute change · L
No placebo or comparator arm
CFB to Day 28
NCT04923347 · Phase 4 · registry result, not featured evidence
FEV1 Trough 0.0317 L @ 12wk
absolute change · L
No placebo or comparator arm
CFB to Day 85
NCT04923347 · Phase 4 · registry result, not featured evidence
CAT Total -6.8 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence
show 1 more result
-4.4 score @ 4wk
NCT05535972 · Phase 4 · registry result, not featured evidence
mMRC Dyspnea Scale -0.5 score @ 12wk
absolute change · score
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence
show 1 more result
-0.5 score @ 12wk
NCT05535972 · Phase 4 · registry result, not featured evidence
CAT 86% (n=422) @ 12wk
responder rate · % of participants
No placebo or comparator arm
NCT05535972 · Phase 4 · registry result, not featured evidence
CAT 47.5% (n=1539) vs 39.9% (n=1543) Non-Ellipta @ 24wk100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
responder rate · % of participants
NCT03467425 · Phase 4 · registry result, not featured evidence · converted to % from 731 Participants as posted
FEV1 1.446 vs 1.396 Non-Ellipta L @ 24wk100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI
absolute change · L
NCT03467425 · Phase 4 · registry result, not featured evidence
FEV1 Wm0 24 h 0.039 vs 0.029 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcg
absolute change · L
NCT03478696 · Phase 4 · registry result, not featured evidence
show 5 more results
0.045 vs 0.041 Budesonide/Formoterol Plus Tiotropium L @ 0.14wk100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
0.04 vs 0.023 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcg
NCT03478696 · Phase 4 · registry result, not featured evidence
0.045 vs 0.03 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
0.054 vs 0.063 Budesonide/Formoterol Plus Tiotropium L @ 0.14wk100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence
0.046 vs 0.032 Budesonide/Formoterol Plus Tiotropium L @ 12wk100/62.5/25 mcg
NCT03478683 · Phase 4 · registry result, not featured evidence

+ 4 further endpoints in the CSV export.

Tiotropium bromide

Time to First Exacerbation 0.1 vs 0.33 TIO months50/250 µg BID
time to event · months
NCT01762800 · Phase 4 · registry result, not featured evidence · converted to months from 3 days as posted
show 5 more results
0.16 vs 0.33 TIO months*50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 5 days as posted
0 vs 0 TIO months*50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · converted to months from 0 days as posted
0 vs 0 TIO months*50/250 µg BID + 18 µg QD
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 0 days as posted
0.07 vs 0.33 TIO months*18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 2 days as posted
0.03 vs 0 TIO months*18 µg QD + 50/250 µg BID
NCT01762800 · Phase 4 · registry result, not featured evidence · combination · converted to months from 1 days as posted
EXACT Total 27.83 vs 28.88 TIO score @ 4wk50/250 µg BID
absolute value · score
Week 1-4; n=120, 67, 109, 73
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
36.92 vs 28.88 TIO score @ 4wk50/250 µg BID + 18 µg QD
Week 1-4; n=120, 67, 109, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
38.26 vs 28.88 TIO score @ 4wk18 µg QD + 50/250 µg BID
Week 1-4; n=120, 67, 109, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 27.35 vs 28.8 TIO score @ 8wk50/250 µg BID
absolute value · score
Week 5-8; n=117, 63, 102, 69
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
37.58 vs 28.8 TIO score @ 8wk50/250 µg BID + 18 µg QD
Week 5-8; n=117, 63, 102, 69
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
35.87 vs 28.8 TIO score @ 8wk18 µg QD + 50/250 µg BID
Week 5-8; n=117, 63, 102, 69
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 27.63 vs 28.4 TIO score @ 12wk50/250 µg BID
absolute value · score
Week 9-12; n=109, 67, 101, 72
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
36.16 vs 28.4 TIO score @ 12wk50/250 µg BID + 18 µg QD
Week 9-12; n=109, 67, 101, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
35.57 vs 28.4 TIO score @ 12wk18 µg QD + 50/250 µg BID
Week 9-12; n=109, 67, 101, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 27.33 vs 28.93 TIO score @ 16wk50/250 µg BID
absolute value · score
Week 13-16; n=105, 65, 100, 71
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
35.92 vs 28.93 TIO score @ 16wk50/250 µg BID + 18 µg QD
Week 13-16; n=105, 65, 100, 71
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
33.79 vs 28.93 TIO score @ 16wk18 µg QD + 50/250 µg BID
Week 13-16; n=105, 65, 100, 71
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 26.98 vs 28.66 TIO score @ 20wk50/250 µg BID
absolute value · score
Week 17-20; n=107, 65, 97, 66
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
34.92 vs 28.66 TIO score @ 20wk50/250 µg BID + 18 µg QD
Week 17-20; n=107, 65, 97, 66
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
34.03 vs 28.66 TIO score @ 20wk18 µg QD + 50/250 µg BID
Week 17-20; n=107, 65, 97, 66
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT Total 26.5 vs 28.8 TIO score @ 24wk50/250 µg BID
absolute value · score
Week 21-24; n=79, 51, 77, 46
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
32.72 vs 28.8 TIO score @ 24wk50/250 µg BID + 18 µg QD
Week 21-24; n=79, 51, 77, 46
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
33.67 vs 28.8 TIO score @ 24wk18 µg QD + 50/250 µg BID
Week 21-24; n=79, 51, 77, 46
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.76 vs 7.18 TIO score @ 4wk50/250 µg BID
absolute value · score
Week 1-4; n=131, 68, 121, 75
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
12.39 vs 7.18 TIO score @ 4wk50/250 µg BID + 18 µg QD
Week 1-4; n=131, 68, 121, 75
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
13.23 vs 7.18 TIO score @ 4wk18 µg QD + 50/250 µg BID
Week 1-4; n=131, 68, 121, 75
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.75 vs 6.99 TIO score @ 8wk50/250 µg BID
absolute value · score
Week 5-8; n=126, 68, 115, 73
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
11.86 vs 6.99 TIO score @ 8wk50/250 µg BID + 18 µg QD
Week 5-8; n=126, 68, 115, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
11.11 vs 6.99 TIO score @ 8wk18 µg QD + 50/250 µg BID
Week 5-8; n=126, 68, 115, 73
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.69 vs 6.7 TIO score @ 12wk50/250 µg BID
absolute value · score
Week 9-12; n=122, 68, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
11.79 vs 6.7 TIO score @ 12wk50/250 µg BID + 18 µg QD
Week 9-12; n=122, 68, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
11.3 vs 6.7 TIO score @ 12wk18 µg QD + 50/250 µg BID
Week 9-12; n=122, 68, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.23 vs 6.82 TIO score @ 16wk50/250 µg BID
absolute value · score
Week 13-16; n=121, 66, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
11.66 vs 6.82 TIO score @ 16wk50/250 µg BID + 18 µg QD
Week 13-16; n=121, 66, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
10.26 vs 6.82 TIO score @ 16wk18 µg QD + 50/250 µg BID
Week 13-16; n=121, 66, 116, 74
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
EXACT-RS Total 6.33 vs 6.85 TIO score @ 20wk50/250 µg BID
absolute value · score
Week 17-20; n=118, 66, 114, 72
NCT01762800 · Phase 4 · registry result, not featured evidence
show 2 more results
10.8 vs 6.85 TIO score @ 20wk50/250 µg BID + 18 µg QD
Week 17-20; n=118, 66, 114, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination
9.89 vs 6.85 TIO score @ 20wk18 µg QD + 50/250 µg BID
Week 17-20; n=118, 66, 114, 72
NCT01762800 · Phase 4 · registry result, not featured evidence · combination

+ 112 further endpoints in the CSV export.

Asthma

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline

fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta

Marketed by GlaxoSmithKline

Approved in Asthmasmall molecule combination
Reliable signal

NCT02924688 · Phase 3 · completed

This was a large (N=2,436) randomized, triple-blind, active-controlled Phase III trial comparing four fixed-dose combinations of fluticasone furoate/umeclidinium/vilanterol against two fluticasone furoate/vilanterol dual therapy controls in patients with inadequately controlled asthma. The primary endpoint, change from baseline in trough FEV1 at Week 24, was met for every pre-specified triple-therapy versus dual-therapy comparison, with all four least-squares mean differences favoring triple therapy and p<0.001. The combination of randomization, blinding, an active comparator, a large sample, a hard clinical endpoint, and a statistically significant primary result constitutes strong evidence.

Next expected readout: January 2027 · NCT05757102 (registry estimate)

Reported efficacy

Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 (Baseline (pre-dose at Day 1) and Week 24): Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001). (met)

Result source: NCT02924688

Tiotropium bromide

Marketed by Boehringer Ingelheim

Approved in Asthmasmall molecule
Reliable signal

NCT00772538 · Phase 3 · completed

The trial randomized 459 participants to double-blind tiotropium or matching placebo, with 237 receiving tiotropium and 222 placebo. The primary comparisons favored tiotropium, including significant improvements in peak and trough FEV1 at 24 weeks and a significant reduction in time to first severe asthma exacerbation in the pooled twin-trial analysis.

Next expected readout: January 2027 · NCT06679465 (registry estimate)

Reported efficacy

Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks); Trough FEV1 Response Determined After a Treatment Period of 24 Weeks. (Baseline and 24 weeks); Time to First Severe Asthma Exacerbation During the 48-week Treatment of the Pooled Data From the Two Twin Trials 205.416 (NCT00772538) and the Present 205.417 (NCT00776984). (48 weeks): Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks): Tio R5 0.401 Liter (Standard Error 0.025) vs Placebo 0.315 Liter (Standard Error 0.026) (met)

Result source: NCT00772538

Results for Asthma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointfluticasone furoate/​umeclidinium/​vilanterolTiotropium bromide
Severe exacerbations, annualised rate—Trial running · NCT04651777—Not reported
Trough FEV1, change0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 FF 100 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 87 · Phase 3 · primary NCT04937387
  • 0.1 vs 0.1 FF 200 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 82 · Phase 3 · secondary NCT04937387
0.1 vs -0.0+0.2 vs placebo2.5 mcg once daily · wk 24 · n 247NCT01172808
40 other results
  • 0.2 vs -0.0 2.5 mcg once daily · wk 24 · n 245 · Phase 3 · primary NCT01172821
  • 0.1 vs 0.1 5 µg/day · wk 24 · n 237 · Phase 3 · primary NCT00772538
  • 0.1 vs -0.0 5 mcg once daily · wk 24 · n 241 · Phase 3 · primary NCT01172808
  • 0.1 vs -0.0 5 mcg once daily · wk 24 · n 240 · Phase 3 · primary NCT01172821
  • 0.2 vs 0.0 5 µg/day · wk 24 · n 216 · Phase 3 · primary NCT00776984
  • 0.3 vs 0.2 2.5 mcg · wk 24 · n 135 · Phase 3 · secondary NCT01634139
  • 0.4 vs 0.3 2.5 mcg · wk 24 · n 119 · Phase 3 · secondary NCT01257230
  • 0.2 vs 0.1 2.5 mcg · wk 12 · n 135 · Phase 3 · secondary NCT01634152
  • 0.3 vs 0.2 2.5 μg · wk 12 · n 126 · Phase 3 · secondary NCT01277523
  • 0.1 vs 0.0 2.5 mcg · wk 12 · n 151 · Phase 3 · secondary NCT01316380
  • 0.3 vs 0.3 2.5 mcg · wk 48 · n 135 · Phase 3 · secondary NCT01634139
  • 0.1 vs 0.1 2.5 µg once daily · wk 52 · n 114 · Phase 3 · secondary NCT01340209
  • 0.3 vs 0.2 5 mcg · wk 24 · n 135 · Phase 3 · secondary NCT01634139
  • 0.4 vs 0.3 5 mcg · wk 24 · n 131 · Phase 3 · secondary NCT01257230
  • 0.2 vs 0.1 5 mcg · wk 12 · n 128 · Phase 3 · secondary NCT01634152
  • 0.3 vs 0.2 5 μg · wk 12 · n 130 · Phase 3 · secondary NCT01277523
  • 0.1 vs 0.0 5 mcg · wk 12 · n 152 · Phase 3 · secondary NCT01316380
  • 0.1 vs 0.1 5 µg/day · wk 48 · n 237 · Phase 3 · secondary NCT00772538
  • 0.4 vs 0.3 5 mcg · wk 48 · n 135 · Phase 3 · secondary NCT01634139
  • 0.2 vs 0.1 5 µg/day · wk 48 · n 216 · Phase 3 · secondary NCT00776984
  • 0.2 vs 0.1 5 µg once daily · wk 52 · n 114 · Phase 3 · secondary NCT01340209
  • 0.2 vs -0.0 1800 μg · wk 0.21 · n 31 · Phase 1 · primary NCT02573155
  • 0.1 vs -0.0 400 μg · wk 0.21 · n 34 · Phase 1 · primary NCT02573155
  • 0.5 vs -0.0 2100 μg · wk 0.21 · n 5 · Phase 1 · primary NCT02573155
  • 0.3 vs -0.0 1800 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.2 vs -0.0 900 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.3 vs -0.0 400 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.2 vs -0.0 200 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • -0.0 vs -0.0 50 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.2 vs 0.1 2.5 mcg · wk 4 · n 74 · Phase 2 · secondary NCT01383499
  • 0.1 vs 0.0 2.5 µg once daily · wk 4 · n 144 · Phase 2 · secondary NCT01233284
  • 0.4 vs 0.3 2.5 mcg · wk 4 · n 74 · Phase 2 · secondary NCT01122680
  • 0.2 vs 0.1 5 mcg · wk 4 · n 75 · Phase 2 · secondary NCT01383499
  • 0.1 vs 0.0 5 µg once daily · wk 4 · n 143 · Phase 2 · secondary NCT01233284
  • 0.3 vs 0.1 5 µg once daily · wk 4 · n 90 · Phase 2 · secondary NCT01152450
  • 0.4 vs 0.3 5 mcg · wk 4 · n 77 · Phase 2 · secondary NCT01122680
  • 0.3 vs 0.1 2.5 µg twice daily · wk 4 · n 89 · Phase 2 · secondary NCT01152450
  • 0.2 vs 0.1 1.25 mcg · wk 4 · n 75 · Phase 2 · secondary NCT01383499
  • 0.1 vs 0.0 1.25 µg once daily · wk 4 · n 144 · Phase 2 · secondary NCT01233284
  • 0.4 vs 0.3 1.25 mcg · wk 4 · n 73 · Phase 2 · secondary NCT01122680
ACQ-5, change—Trial running · NCT04651777—Not reported
OCS dose reduction—Trial running · NCT04651777—Not reported

Severe exacerbations, annualised rate

fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777
Tiotropium bromide
—Not reported

Trough FEV1, change

fluticasone furoate/​umeclidinium/​vilanterol
0.1 vs 0.1vs FF/VI100/31.25/25 mcg · wk 24 · n 399NCT02924688
5 other results
  • 0.2 vs 0.1 200/31.25/25 mcg · wk 24 · n 399 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 100/62.5/25 mcg · wk 24 · n 404 · Phase 3 · primary NCT02924688
  • 0.2 vs 0.1 200/62.5/25 mcg · wk 24 · n 405 · Phase 3 · primary NCT02924688
  • 0.1 vs 0.1 FF 100 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 87 · Phase 3 · primary NCT04937387
  • 0.1 vs 0.1 FF 200 ug, UMEC 62.5 ug, VI 25 ug · wk 12 · n 82 · Phase 3 · secondary NCT04937387
Tiotropium bromide
0.1 vs -0.0+0.2 vs placebo2.5 mcg once daily · wk 24 · n 247NCT01172808
40 other results
  • 0.2 vs -0.0 2.5 mcg once daily · wk 24 · n 245 · Phase 3 · primary NCT01172821
  • 0.1 vs 0.1 5 µg/day · wk 24 · n 237 · Phase 3 · primary NCT00772538
  • 0.1 vs -0.0 5 mcg once daily · wk 24 · n 241 · Phase 3 · primary NCT01172808
  • 0.1 vs -0.0 5 mcg once daily · wk 24 · n 240 · Phase 3 · primary NCT01172821
  • 0.2 vs 0.0 5 µg/day · wk 24 · n 216 · Phase 3 · primary NCT00776984
  • 0.3 vs 0.2 2.5 mcg · wk 24 · n 135 · Phase 3 · secondary NCT01634139
  • 0.4 vs 0.3 2.5 mcg · wk 24 · n 119 · Phase 3 · secondary NCT01257230
  • 0.2 vs 0.1 2.5 mcg · wk 12 · n 135 · Phase 3 · secondary NCT01634152
  • 0.3 vs 0.2 2.5 μg · wk 12 · n 126 · Phase 3 · secondary NCT01277523
  • 0.1 vs 0.0 2.5 mcg · wk 12 · n 151 · Phase 3 · secondary NCT01316380
  • 0.3 vs 0.3 2.5 mcg · wk 48 · n 135 · Phase 3 · secondary NCT01634139
  • 0.1 vs 0.1 2.5 µg once daily · wk 52 · n 114 · Phase 3 · secondary NCT01340209
  • 0.3 vs 0.2 5 mcg · wk 24 · n 135 · Phase 3 · secondary NCT01634139
  • 0.4 vs 0.3 5 mcg · wk 24 · n 131 · Phase 3 · secondary NCT01257230
  • 0.2 vs 0.1 5 mcg · wk 12 · n 128 · Phase 3 · secondary NCT01634152
  • 0.3 vs 0.2 5 μg · wk 12 · n 130 · Phase 3 · secondary NCT01277523
  • 0.1 vs 0.0 5 mcg · wk 12 · n 152 · Phase 3 · secondary NCT01316380
  • 0.1 vs 0.1 5 µg/day · wk 48 · n 237 · Phase 3 · secondary NCT00772538
  • 0.4 vs 0.3 5 mcg · wk 48 · n 135 · Phase 3 · secondary NCT01634139
  • 0.2 vs 0.1 5 µg/day · wk 48 · n 216 · Phase 3 · secondary NCT00776984
  • 0.2 vs 0.1 5 µg once daily · wk 52 · n 114 · Phase 3 · secondary NCT01340209
  • 0.2 vs -0.0 1800 μg · wk 0.21 · n 31 · Phase 1 · primary NCT02573155
  • 0.1 vs -0.0 400 μg · wk 0.21 · n 34 · Phase 1 · primary NCT02573155
  • 0.5 vs -0.0 2100 μg · wk 0.21 · n 5 · Phase 1 · primary NCT02573155
  • 0.3 vs -0.0 1800 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.2 vs -0.0 900 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.3 vs -0.0 400 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.2 vs -0.0 200 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • -0.0 vs -0.0 50 μg · wk 0.21 · n 6 · Phase 1 · primary NCT02573155
  • 0.2 vs 0.1 2.5 mcg · wk 4 · n 74 · Phase 2 · secondary NCT01383499
  • 0.1 vs 0.0 2.5 µg once daily · wk 4 · n 144 · Phase 2 · secondary NCT01233284
  • 0.4 vs 0.3 2.5 mcg · wk 4 · n 74 · Phase 2 · secondary NCT01122680
  • 0.2 vs 0.1 5 mcg · wk 4 · n 75 · Phase 2 · secondary NCT01383499
  • 0.1 vs 0.0 5 µg once daily · wk 4 · n 143 · Phase 2 · secondary NCT01233284
  • 0.3 vs 0.1 5 µg once daily · wk 4 · n 90 · Phase 2 · secondary NCT01152450
  • 0.4 vs 0.3 5 mcg · wk 4 · n 77 · Phase 2 · secondary NCT01122680
  • 0.3 vs 0.1 2.5 µg twice daily · wk 4 · n 89 · Phase 2 · secondary NCT01152450
  • 0.2 vs 0.1 1.25 mcg · wk 4 · n 75 · Phase 2 · secondary NCT01383499
  • 0.1 vs 0.0 1.25 µg once daily · wk 4 · n 144 · Phase 2 · secondary NCT01233284
  • 0.4 vs 0.3 1.25 mcg · wk 4 · n 73 · Phase 2 · secondary NCT01122680

ACQ-5, change

fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777
Tiotropium bromide
—Not reported

OCS dose reduction

fluticasone furoate/​umeclidinium/​vilanterol
—Trial running · NCT04651777
Tiotropium bromide
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. fluticasone furoate/umeclidinium/vilanterol: 4 of 4 rows · Tiotropium bromide: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricfluticasone furoate/​umeclidinium/​vilanterolTiotropium bromide
Dropout rate
7.7%100/31.25/25 mcga
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.9%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
3.4%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
0%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
11.1%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
7.3%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
11%5 µg/dayb
NCT00772538 · Phase 3
show 39 more results
—
NCT00565266 · Phase 3 · combination · Asthma · phase 3
4.4%2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
3.7%5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.7%2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
3.1%5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
8%2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
4.4%5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.8%2.5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0%5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
7%2.5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
7%5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
5%2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
8.7%5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
4.7%2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
5.1%5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
3.2%2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
1.9%5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
9.6%5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
—5 µg QD
NCT01696071 · Phase 2 · registry result, not featured evidence
—2.5 µg BID
NCT01696071 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
—2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
—5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
—1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
—2.5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
—5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
—2100 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—1800 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—1800 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—900 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—400 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—400 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—200 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—50 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs
0.7%100/31.25/25 mcga
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
0.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.5%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.5%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
0%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
1.8%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
2.5%5 µg/dayb
NCT00772538 · Phase 3
show 39 more results
—
NCT00565266 · Phase 3 · combination · Asthma · phase 3
—2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
—5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0%2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
1.5%5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0%2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0%5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0%2.5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0%5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.9%2.5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
1.8%5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
1.5%2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
3%5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.8%2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.8%5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
1.3%2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.6%5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.9%5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
—5 µg QD
NCT01696071 · Phase 2 · registry result, not featured evidence
—2.5 µg BID
NCT01696071 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
—2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
—5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
—1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
—2.5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
—5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
—2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
—5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
—1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
—2100 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—1800 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—1800 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—900 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—400 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—400 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—200 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
—50 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
Serious AEs
4.4%100/31.25/25 mcga
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
5.7%200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.7%100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
5.1%200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
1.1%FF 200 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
3.3%FF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3
2.1%100/62.5/25 mcg
NCT03184987 · Phase 3 · combination
0%100/62.5/25 mcg to 200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
3.6%200/62.5/25 mcg
NCT03184987 · Phase 3 · combination
7.6%5 µg/dayb
NCT00772538 · Phase 3
show 39 more results
1.5%
NCT00565266 · Phase 3 · combination · Asthma · phase 3
2.2%2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.7%5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
1.5%2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
3.1%5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
1.6%2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
2.2%5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.8%2.5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
1.5%5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
3.5%2.5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
3.5%5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
1.9%2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
1.5%5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
2.7%2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
2.8%5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0%2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.6%5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
8.7%5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0%5 µg QD
NCT01696071 · Phase 2 · registry result, not featured evidence
1%2.5 µg BID
NCT01696071 · Phase 2 · registry result, not featured evidence
0%2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0%5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0%1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0%2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
1.4%5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0%1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0%2.5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
2.2%5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0%2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
1.3%5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
1.3%1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0%2100 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
0%1800 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
0%1800 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
0%900 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
0%400 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
2.9%400 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
0%200 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
0%50 μg
NCT02573155 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs
100/31.25/25 mcga
nasopharyngitis 13.8%
headache 7.7%
upper respiratory tract infection 5.9%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 8 more results
200/31.25/25 mcg
nasopharyngitis 12.6%
headache 6.7%
bronchitis 4%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
100/62.5/25 mcg
nasopharyngitis 14.8%
headache 8.9%
bronchitis 3.7%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
200/62.5/25 mcg
nasopharyngitis 12.5%
bronchitis 5.4%
headache 4.7%
NCT02924688 · Phase 3 · combination · Asthma · phase 3
FF 200 ug, UMEC 62.5 ug, VI 25 ug
covid-19 5.7%
nasopharyngitis 4.5%
upper respiratory tract infection 4.5%
NCT04937387 · Phase 3 · Asthma · phase 3
FF 100 ug, UMEC 62.5 ug, VI 25 ug
upper respiratory tract infection 7.8%
covid-19 3.3%
nasopharyngitis 3.3%
NCT04937387 · Phase 3 · Asthma · phase 3
100/62.5/25 mcg
nasopharyngitis 27.7%
pharyngitis 10.6%
bronchitis 8.5%
NCT03184987 · Phase 3 · combination
100/62.5/25 mcg to 200/62.5/25 mcg
bronchitis 22.2%
dysgeusia 22.2%
nasopharyngitis 22.2%
NCT03184987 · Phase 3 · combination
200/62.5/25 mcg
nasopharyngitis 32.7%
dysgeusia 10.9%
eczema 9.1%
NCT03184987 · Phase 3 · combination
5 µg/dayb
asthma 34.6% (placebo 44.6%)
peak expiratory flow rate decreased 20.7% (placebo 26.1%)
nasopharyngitis 8% (placebo 9%)
NCT00772538 · Phase 3
show 28 more results
urgent care visit due to asthma 1%
NCT00565266 · Phase 3 · combination · Asthma · phase 3
2.5 mcg
asthma 36.3% (placebo 43.5%)
peak expiratory flow rate decreased 23% (placebo 20.6%)
nasopharyngitis 11.1% (placebo 9.9%)
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
5 mcg
asthma 34.1% (placebo 43.5%)
peak expiratory flow rate decreased 21.5% (placebo 20.6%)
respiratory tract infection 9.6% (placebo 12.2%)
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
2.5 mcg
asthma 14.7% (placebo 21.6%)
peak expiratory flow rate decreased 11% (placebo 14.9%)
nasopharyngitis 4.4% (placebo 8.2%)
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
5 mcg
asthma 16.9% (placebo 21.6%)
peak expiratory flow rate decreased 11.5% (placebo 14.9%)
nasopharyngitis 4.6% (placebo 8.2%)
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
2.5 mcg
asthma 21.6% (placebo 23.2%)
nasopharyngitis 10.4% (placebo 12.3%)
respiratory tract infection viral 8.8% (placebo 8%)
NCT01257230 · Phase 3 · registry result, not featured evidence
5 mcg
asthma 16.4% (placebo 23.2%)
nasopharyngitis 14.9% (placebo 12.3%)
respiratory tract infection viral 7.5% (placebo 8%)
NCT01257230 · Phase 3 · registry result, not featured evidence
2.5 μg
asthma 11% (placebo 10.4%)
peak expiratory flow rate decreased 7.1% (placebo 9.6%)
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
5 μg
asthma 10.8% (placebo 10.4%)
peak expiratory flow rate decreased 3.8% (placebo 9.6%)
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
2.5 µg once daily
nasopharyngitis 44.7% (placebo 42.1%)
asthma 29.8% (placebo 36.8%)
bronchitis 13.2% (placebo 7%)
NCT01340209 · Phase 3 · registry result, not featured evidence
5 µg once daily
nasopharyngitis 48.2% (placebo 42.1%)
asthma 28.1% (placebo 36.8%)
peak expiratory flow rate decreased 15.8% (placebo 21.1%)
NCT01340209 · Phase 3 · registry result, not featured evidence
2.5 mcg once daily
asthma 13.7% (placebo 21.6%)
peak expiratory flow rate decreased 10.7% (placebo 19%)
nasopharyngitis 6.9% (placebo 8.2%)
NCT01172808 · Phase 3 · registry result, not featured evidence
5 mcg once daily
asthma 22.7% (placebo 21.6%)
peak expiratory flow rate decreased 12.9% (placebo 19%)
nasopharyngitis 8.3% (placebo 8.2%)
NCT01172808 · Phase 3 · registry result, not featured evidence
2.5 mcg once daily
asthma 17.1% (placebo 21.3%)
nasopharyngitis 12.1% (placebo 10.2%)
peak expiratory flow rate decreased 8.2% (placebo 11%)
NCT01172821 · Phase 3 · registry result, not featured evidence
5 mcg once daily
asthma 19.8% (placebo 21.3%)
peak expiratory flow rate decreased 9.9% (placebo 11%)
nasopharyngitis 7.5% (placebo 10.2%)
NCT01172821 · Phase 3 · registry result, not featured evidence
2.5 mcg
asthma 15.6% (placebo 12.3%)
peak expiratory flow rate decreased 5.8% (placebo 3.9%)
NCT01316380 · Phase 3 · registry result, not featured evidence
5 mcg
asthma 11% (placebo 12.3%)
peak expiratory flow rate decreased 3.9% (placebo 3.9%)
NCT01316380 · Phase 3 · registry result, not featured evidence
5 µg/day
asthma 37.9% (placebo 47.9%)
peak expiratory flow rate decreased 20.1% (placebo 27.4%)
nasopharyngitis 14.6% (placebo 15.4%)
NCT00776984 · Phase 3 · registry result, not featured evidence
2.5 µg once daily
headache 7.8% (placebo 4.3%)
NCT01152450 · Phase 2 · registry result, not featured evidence
5 µg once daily
headache 5.6% (placebo 4.3%)
NCT01152450 · Phase 2 · registry result, not featured evidence
2100 μg
nasopharyngitis 40% (placebo 8.3%)
bronchitis viral 20% (placebo 0%)
feeling hot 20% (placebo 8.3%)
NCT02573155 · Phase 1 · registry result, not featured evidence
1800 μg
headache 16.7% (placebo 25%)
nausea 16.7% (placebo 0%)
neck pain 16.7% (placebo 0%)
NCT02573155 · Phase 1 · registry result, not featured evidence
1800 μg
headache 9.7% (placebo 25%)
chronic obstructive pulmonary disorder 3.2% (placebo 0%)
nasopharyngitis 3.2% (placebo 8.3%)
NCT02573155 · Phase 1 · registry result, not featured evidence
900 μg
headache 33.3% (placebo 25%)
back pain 16.7% (placebo 0%)
cough 16.7% (placebo 0%)
NCT02573155 · Phase 1 · registry result, not featured evidence
400 μg
headache 33.3% (placebo 25%)
back pain 16.7% (placebo 0%)
neck pain 16.7% (placebo 0%)
NCT02573155 · Phase 1 · registry result, not featured evidence
400 μg
headache 14.7% (placebo 25%)
chronic obstructive pulmonary disorder 5.9% (placebo 0%)
nasopharyngitis 2.9% (placebo 8.3%)
NCT02573155 · Phase 1 · registry result, not featured evidence
200 μg
abscess oral 16.7% (placebo 0%)
chest discomfort 16.7% (placebo 8.3%)
chest pain 16.7% (placebo 0%)
NCT02573155 · Phase 1 · registry result, not featured evidence
50 μg
headache 50% (placebo 25%)
nasopharyngitis 50% (placebo 8.3%)
back pain 16.7% (placebo 0%)
NCT02573155 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for 3 of these studies.
  2. bPopulation comparability has not been reviewed for 39 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

fluticasone furoate/umeclidinium/vilanterol

FEV1 Change 3 h 0.22 vs 0.132 FF/VI L @ 24wk100/31.25/25 mcg
absolute change · L
NCT02924688 · Phase 3 · combination · Asthma · phase 3
show 3 more results
0.256 vs 0.132 FF/VI L @ 24wk200/31.25/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.243 vs 0.132 FF/VI L @ 24wk100/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
0.286 vs 0.132 FF/VI L @ 24wk200/62.5/25 mcg
NCT02924688 · Phase 3 · combination · Asthma · phase 3
ACQ-7 -0.814 vs -0.94 Fluticasone Furoate [FF] / Vilanterol [VI] score @ 12wkFF 200 ug, UMEC 62.5 ug, VI 25 ug
absolute change · score
NCT04937387 · Phase 3 · Asthma · phase 3
show 1 more result
-0.968 vs -0.94 Fluticasone Furoate [FF] / Vilanterol [VI] score @ 12wkFF 100 ug, UMEC 62.5 ug, VI 25 ug
NCT04937387 · Phase 3 · Asthma · phase 3

Tiotropium bromide

FEV1 Peak 0.395 vs 0.225 placebo L @ 24wk2.5 mcg
absolute change · L
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
show 30 more results
0.474 vs 0.351 placebo L @ 48wk2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.287 vs 0.252 placebo L @ 12wk2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.507 vs 0.373 placebo L @ 24wk2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.55 vs 0.438 placebo L @ 12wk2.5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.289 vs 0.053 placebo L @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.287 vs 0.075 placebo L @ 24wk2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.293 vs 0.134 placebo L @ 12wk2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.29 vs 0.185 placebo L @ 4wk2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.244 vs 0.116 placebo L2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.546 vs 0.489 placebo L @ 4wk2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.401 vs 0.315 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.367 vs 0.295 placebo L @ 48wk5 µg/day
NCT00772538 · Phase 3
0.389 vs 0.225 placebo L @ 24wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.477 vs 0.351 placebo L @ 48wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.391 vs 0.252 placebo L @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.547 vs 0.373 placebo L @ 24wk5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.528 vs 0.438 placebo L @ 12wk5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.25 vs 0.053 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.244 vs 0.075 placebo L @ 24wk5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.262 vs 0.134 placebo L @ 12wk5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.401 vs 0.248 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.397 vs 0.245 placebo L @ 48wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.272 vs 0.185 placebo L @ 4wk5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.304 vs 0.116 placebo L5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.468 vs 0.337 placebo L @ 4wk5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.602 vs 0.489 placebo L @ 4wk5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.469 vs 0.337 placebo L @ 4wk2.5 µg twice daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.261 vs 0.185 placebo L @ 4wk1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.255 vs 0.116 placebo L1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.556 vs 0.489 placebo L @ 4wk1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
Time to First Severe Exacerbation NA vs NA placebo months @ 24wk2.5 mcg once daily
time to event · months
NCT01172808 · Phase 3 · registry result, not featured evidence
show 7 more results
NA vs NA placebo months2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
NA vs NA placebo months2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
NA vs NA placebo months @ 48wk5 µg/day
NCT00772538 · Phase 3
NA vs NA placebo months @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
NA vs NA placebo months5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
NA vs NA placebo months5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
NA vs NA placebo months5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
FVC Peak 0.325 vs 0.215 placebo L @ 24wk2.5 mcg
absolute change · L
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
show 30 more results
0.43 vs 0.361 placebo L @ 48wk2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.201 vs 0.244 placebo L @ 12wk2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.419 vs 0.331 placebo L @ 24wk2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.37 vs 0.279 placebo L @ 12wk2.5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.219 vs 0.045 placebo L @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.181 vs 0.071 placebo L @ 24wk2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.231 vs 0.126 placebo L @ 12wk2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.253 vs 0.202 placebo L @ 4wk2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.163 vs 0.092 placebo L2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.554 vs 0.546 placebo L @ 4wk2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.445 vs 0.355 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.462 vs 0.337 placebo L @ 48wk5 µg/day
NCT00772538 · Phase 3
0.307 vs 0.215 placebo L @ 24wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.413 vs 0.361 placebo L @ 48wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.275 vs 0.244 placebo L @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.403 vs 0.331 placebo L @ 24wk5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.342 vs 0.279 placebo L @ 12wk5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.148 vs 0.045 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.16 vs 0.071 placebo L @ 24wk5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.183 vs 0.126 placebo L @ 12wk5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.416 vs 0.323 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.42 vs 0.305 placebo L @ 48wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.239 vs 0.202 placebo L @ 4wk5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.229 vs 0.092 placebo L5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.35 vs 0.302 placebo L @ 4wk5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.548 vs 0.546 placebo L @ 4wk5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.38 vs 0.302 placebo L @ 4wk2.5 µg twice daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.208 vs 0.202 placebo L @ 4wk1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.171 vs 0.092 placebo L1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.554 vs 0.546 placebo L @ 4wk1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
FVC Trough 0.246 vs 0.154 placebo L @ 24wk2.5 mcg
absolute change · L
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
show 28 more results
0.341 vs 0.28 placebo L @ 48wk2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.094 vs 0.141 placebo L @ 12wk2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.345 vs 0.281 placebo L @ 24wk2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.085 vs 0.122 placebo L @ 52wk2.5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
0.086 vs -0.039 placebo L @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.039 vs -0.048 placebo L @ 24wk2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.107 vs 0.06 placebo L @ 4wk2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.076 vs 0.004 placebo L @ 4wk2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.381 vs 0.357 placebo L @ 4wk2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.157 vs 0.022 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.173 vs 0.062 placebo L @ 48wk5 µg/day
NCT00772538 · Phase 3
0.206 vs 0.154 placebo L @ 24wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.333 vs 0.28 placebo L @ 48wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.15 vs 0.141 placebo L @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.316 vs 0.281 placebo L @ 24wk5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.204 vs 0.122 placebo L @ 52wk5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
0.036 vs -0.039 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.035 vs -0.048 placebo L @ 24wk5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.15 vs 0.044 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.142 vs 0.072 placebo L @ 48wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.113 vs 0.06 placebo L @ 4wk5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.102 vs 0.004 placebo L @ 4wk5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.168 vs 0.112 placebo L @ 4wk5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.4 vs 0.357 placebo L @ 4wk5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.179 vs 0.112 placebo L @ 4wk2.5 µg twice daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.109 vs 0.06 placebo L @ 4wk1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.058 vs 0.004 placebo L @ 4wk1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.375 vs 0.357 placebo L @ 4wk1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
FEV1 AUC0-3 0.192 vs -0.033 placebo L @ 24wk2.5 mcg once daily
absolute change · L
NCT01172808 · Phase 3 · registry result, not featured evidence
show 5 more results
0.315 vs 0.229 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.289 vs 0.217 placebo L @ 48wk5 µg/day
NCT00772538 · Phase 3
0.163 vs -0.033 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.307 vs 0.164 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.31 vs 0.172 placebo L @ 48wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
FVC AUC(0-3 0.105 vs 0.145 placebo L @ 12wk2.5 mcg
absolute change · L
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
show 22 more results
0.33 vs 0.24 placebo L @ 24wk2.5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.262 vs 0.175 placebo L @ 12wk2.5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.092 vs -0.066 placebo L @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.101 vs 0 placebo L @ 12wk2.5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.134 vs 0.087 placebo L @ 4wk2.5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.047 vs -0.028 placebo L2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.417 vs 0.413 placebo L @ 4wk2.5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.328 vs 0.23 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.344 vs 0.223 placebo L @ 48wk5 µg/day
NCT00772538 · Phase 3
0.182 vs 0.145 placebo L @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.311 vs 0.24 placebo L @ 24wk5 mcg
NCT01257230 · Phase 3 · registry result, not featured evidence
0.227 vs 0.175 placebo L @ 12wk5 μg
NCT01277523 · Phase 3 · registry result, not featured evidence · add on
0.041 vs -0.066 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.061 vs 0 placebo L @ 12wk5 mcg
NCT01316380 · Phase 3 · registry result, not featured evidence
0.295 vs 0.187 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.299 vs 0.19 placebo L @ 48wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
0.11 vs 0.087 placebo L @ 4wk5 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.11 vs -0.028 placebo L5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.429 vs 0.413 placebo L @ 4wk5 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
0.097 vs 0.087 placebo L @ 4wk1.25 mcg
NCT01383499 · Phase 2 · registry result, not featured evidence
0.036 vs -0.028 placebo L1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.441 vs 0.413 placebo L @ 4wk1.25 mcg
NCT01122680 · Phase 2 · registry result, not featured evidence
Morning PEF 10.934 vs 2.288 placebo L/min @ 52wk2.5 µg once daily
absolute change · L/min
NCT01340209 · Phase 3 · registry result, not featured evidence
show 5 more results
15.297 vs -6.996 placebo L/min @ 24wk5 µg/day
NCT00772538 · Phase 3
8.504 vs 2.288 placebo L/min @ 52wk5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
17.396 vs -3.258 placebo L/min @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
24.31 vs 1.953 placebo L/min @ 4wk5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
23.281 vs 1.953 placebo L/min @ 4wk2.5 µg twice daily
NCT01152450 · Phase 2 · registry result, not featured evidence
Evening PEF 1.101 vs -10.357 placebo L/min @ 52wk2.5 µg once daily
absolute change · L/min
NCT01340209 · Phase 3 · registry result, not featured evidence
show 5 more results
19.402 vs -3.865 placebo L/min @ 24wk5 µg/day
NCT00772538 · Phase 3
6.041 vs -10.357 placebo L/min @ 52wk5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
25.158 vs -7.295 placebo L/min @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
27.096 vs -1.56 placebo L/min @ 4wk5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
28.36 vs -1.56 placebo L/min @ 4wk2.5 µg twice daily
NCT01152450 · Phase 2 · registry result, not featured evidence
FEV1 Morning 0.209 vs 0.191 placebo L @ 24wk2.5 mcg
absolute change · L
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
show 11 more results
0.259 vs 0.236 placebo L @ 48wk2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.142 vs 0.174 placebo L @ 12wk2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.101 vs 0.021 placebo L @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.099 vs 0.02 placebo L @ 24wk2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.062 vs -0.055 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.126 vs 0.191 placebo L @ 24wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.221 vs 0.236 placebo L @ 48wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.125 vs 0.174 placebo L @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.073 vs 0.021 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.084 vs 0.02 placebo L @ 24wk5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.096 vs 0.006 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
FEV1 Evening 0.142 vs 0.167 placebo L @ 24wk2.5 mcg
absolute change · L
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
show 11 more results
0.208 vs 0.202 placebo L @ 48wk2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.104 vs 0.155 placebo L @ 12wk2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.065 vs 0 placebo L @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.066 vs -0.002 placebo L @ 24wk2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.075 vs -0.05 placebo L @ 24wk5 µg/day
NCT00772538 · Phase 3
0.092 vs 0.167 placebo L @ 24wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.159 vs 0.202 placebo L @ 48wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
0.094 vs 0.155 placebo L @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.039 vs 0 placebo L @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
0.064 vs -0.002 placebo L @ 24wk5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
0.122 vs -0.015 placebo L @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
PEF Variability -0.942% (n=135) vs -1.204% (n=131) placebo @ 24wk2.5 mcg
absolute change · percentage points
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
show 18 more results
-0.048% (n=135) vs -0.32% (n=131) placebo @ 48wk2.5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
-0.8% (n=136) vs 0.15% (n=127) placebo @ 12wk2.5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
-0.968% (n=114) vs -0.367% (n=56) placebo @ 52wk2.5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
-1.958% (n=244) vs -1.4% (n=237) placebo @ 24wk2.5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
-1.401% (n=237) vs -0.448% (n=232) placebo @ 24wk2.5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
-0.711% (n=146) vs -0.171% (n=142) placebo @ 4wk2.5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
-0.714% (n=237) vs -0.997% (n=222) placebo @ 24wk5 µg/day
NCT00772538 · Phase 3
-1.038% (n=135) vs -1.204% (n=131) placebo @ 24wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
-0.899% (n=135) vs -0.32% (n=131) placebo @ 48wk5 mcg
NCT01634139 · Phase 3 · registry result, not featured evidence · add on
-0.352% (n=125) vs 0.15% (n=127) placebo @ 12wk5 mcg
NCT01634152 · Phase 3 · registry result, not featured evidence · add on
0.197% (n=114) vs -0.367% (n=56) placebo @ 52wk5 µg once daily
NCT01340209 · Phase 3 · registry result, not featured evidence
0.18% (n=234) vs -1.4% (n=237) placebo @ 24wk5 mcg once daily
NCT01172808 · Phase 3 · registry result, not featured evidence
-0.627% (n=234) vs -0.448% (n=232) placebo @ 24wk5 mcg once daily
NCT01172821 · Phase 3 · registry result, not featured evidence
-0.611% (n=216) vs -1.808% (n=232) placebo @ 24wk5 µg/day
NCT00776984 · Phase 3 · registry result, not featured evidence
-0.248% (n=144) vs -0.171% (n=142) placebo @ 4wk5 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
0.685% (n=88) vs 0.296% (n=91) placebo @ 4wk5 µg once daily
NCT01152450 · Phase 2 · registry result, not featured evidence
0.619% (n=89) vs 0.296% (n=91) placebo @ 4wk2.5 µg twice daily
NCT01152450 · Phase 2 · registry result, not featured evidence
-0.285% (n=146) vs -0.171% (n=142) placebo @ 4wk1.25 µg once daily
NCT01233284 · Phase 2 · registry result, not featured evidence · add on
Asthma Exacerbation Free 51.1% (n=237) vs 38.3% (n=222) placebo @ 48wk5 µg/day
responder rate · % of participants
0 exacerbations
NCT00772538 · Phase 3 · converted to % from 121 Participants as posted

+ 73 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/umeclidinium/vilanterol's landscape · Tiotropium bromide's landscape